Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …

Introduction Tumour necrosis factor (TNF)‐α antagonists are effective for the treatment of
plaque‐type psoriasis and psoriatic arthritis, but concerns remain about the safety of these …

Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …

Background Drug survival (time to drug discontinuation) has recently emerged as an
important parameter reflecting the long‐term therapeutic performance in a real‐life setting …

Background An unmet need remains for safe and effective long‐term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

Drug survival measures the length of time until discontinuation of a drug. The length of time
a patient remains on a biologic drug is impacted by several factors such as tolerability, side …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

Background Ustekinumab is a monoclonal antibody that targets interleukin (IL)‐12/23 p40 to
treat psoriasis. The IL‐12 pathway is also important in regulating immunity to Mycobacterium …